Search Results for "RNAi"

Alnylam is committed to providing the healthcare community with balanced, accurate, and high-quality information about our science, therapeutic areas, and products.

More than one search term is recommended to yield the most relevant results. By searching, you confirm that your query is unsolicited.

For more information about our FDA-approved therapies, please see the Full Prescribing Information:

HELIOS-A: Efficacy and safety of vutrisiran in patients with hATTR with polyneuropathy

Summary of the efficacy and safety results of vutrisiran compared to external placebo for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy, as published in the journal Amyloid, 2022.

NfL Levels Significantly Decrease in Response to Treatment with Patisiran or Vutrisiran in hATTR Amyloidosis with Polyneuropathy

Consistent antihypertensive efficacy of the RNA interference therapeutic zilebesiran: Subgroup results from the KARDIA-1 phase 2 study in patients with hypertension

RNA Interference With Zilebesiran for Mild to Moderate Hypertension: The KARDIA-1 Randomized Clinical Trial

ATTRv-PN Expert Opinion Slide Deck

Recommendations from a panel of experts for the diagnosis and treatment of hereditary transthyretin amyloidosis with polyneuropathy in the United States.

Safety and Tolerability of ALN-AGT, an RNA Interference Therapeutic Targeting Hepatic Angiotensinogen Synthesis, in Hypertensive Patients during Sodium Depletion or Irbesartan Coadministration

Zilebesiran, an RNA Interference Therapeutic Agent for Hypertension

Durable Reductions in Circulating Angiotensinogen and Blood Pressure 6 Months after Single Doses of ALN-AGT, an RNA Interference Therapeutic Targeting Hepatic Angiotensinogen Synthesis, in Hypertensive Patients

GRAPHICAL ABSTRACT: KARDIA-3 Study Design: Zilebesiran as Add-On Therapy in Patients with High Cardiovascular Risk and Hypertension Inadequately Controlled by Standard of Care Antihypertensives

Insights from the HELIOS-A Study

This deck highlights data from the Phase 3 HELIOS-A trial of vutrisiran in patients with hATTR-PN.

For further information regarding your request, please connect with us by reaching out to your local Medical Science Liaison or contacting our Medical Information team.